UK markets open in 3 hours 32 minutes

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.2500-0.1500 (-4.41%)
At close: 04:00PM EDT
3.2900 +0.04 (+1.23%)
After hours: 07:16PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.4000
Bid3.2500 x 800
Ask3.3000 x 1200
Day's range3.1700 - 3.3600
52-week range2.9500 - 17.8100
Avg. volume785,149
Market cap539.094M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings date15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est23.96
  • Globe Newswire

    atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

    - atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers - EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic stress disorder (PTSD) and other indications NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) --

  • Globe Newswire

    atai Life Sciences to Participate in September Investor Events

    NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright’s 24th Annual Global Investment Conference

  • Globe Newswire

    atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

    - Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,